These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21454723)

  • 1. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
    Lachin JM; Viberti G; Zinman B; Haffner SM; Aftring RP; Paul G; Kravitz BG; Herman WH; Holman RR; Kahn SE;
    Clin J Am Soc Nephrol; 2011 May; 6(5):1032-40. PubMed ID: 21454723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
    Bakris GL; Ruilope LM; McMorn SO; Weston WM; Heise MA; Freed MI; Porter LE
    J Hypertens; 2006 Oct; 24(10):2047-55. PubMed ID: 16957566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
    August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
    Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
    Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Garber A; Klein E; Bruce S; Sankoh S; Mohideen P
    Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
    Kahn SE; Lachin JM; Zinman B; Haffner SM; Aftring RP; Paul G; Kravitz BG; Herman WH; Viberti G; Holman RR;
    Diabetes; 2011 May; 60(5):1552-60. PubMed ID: 21415383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
    N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone reduces urinary albumin excretion in type II diabetes.
    Bakris G; Viberti G; Weston WM; Heise M; Porter LE; Freed MI
    J Hum Hypertens; 2003 Jan; 17(1):7-12. PubMed ID: 12571611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
    Gupta M; Braga MB; Verma S
    Can J Cardiol; 2008 Oct; 24(10):e65-9. PubMed ID: 18841263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
    Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
    Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of incident oral antidiabetic drugs on kidney function.
    Hung AM; Roumie CL; Greevy RA; Liu X; Grijalva CG; Murff HJ; Ikizler TA; Griffin MR
    Kidney Int; 2012 Apr; 81(7):698-706. PubMed ID: 22258320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
    Petrica L; Petrica M; Vlad A; Dragos Jianu C; Gluhovschi G; Ianculescu C; Dumitrascu V; Giju S; Gluhovschi C; Bob F; Ursoniu S; Gadalean F; Velciov S; Bozdog G; Marian R
    Wien Klin Wochenschr; 2009; 121(23-24):765-75. PubMed ID: 20047115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
    Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
    Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial.
    Bjornstad P; Nehus E; El Ghormli L; Bacha F; Libman IM; McKay S; Willi SM; Laffel L; Arslanian S; Nadeau KJ;
    Am J Kidney Dis; 2018 Jan; 71(1):65-74. PubMed ID: 29157731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
    Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
    J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Haffner SM; Viberti G; Herman WH; Lachin JM; Kravitz BG; Yu D; Paul G; Holman RR; Zinman B;
    Diabetes Care; 2010 Jan; 33(1):177-83. PubMed ID: 19808911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.